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Chronicpainisexperienced by asmanyas90%ofcancerpatientsatsomepointduringthedisease.Thispaincanbe directly cancer
related or arise from a sensory neuropathy related to chemotherapy. Major pharmacologicalagents used to treat cancer pain often
lack anatomical speciﬁcity and can have oﬀ-target eﬀects that create new sources of suﬀering. These concerns establish a need for
improved cancer pain management. Gene therapy is emerging as an exciting prospect. This paper discusses the potential for viral
vector-based treatment of cancer pain. It describes studies involving vector delivery of transgenes to laboratory pain models to
modulate the nociceptive cascade. It also discusses clinical investigations aimed at regulating pain in cancer patients. Considering
the prevalence of pain amongcancer patients and the growing potential of gene therapy, these studies could set the stage for a new
class of medicines that selectively disrupt nociceptive signalingwith limited oﬀ-target eﬀects.
1.Introduction
The inabilitytocontrolchronicpain remains oneofthemost
signiﬁcant clinical problems facing the medical establish-
ment. Although the neuroanatomy of pain is relatively well
understood,meaningfulmodulationofnociceptivepathways
has not been established. Pain persists in association with a
number of disorders, and its origin is not always apparent.
In fact, it is one of the symptoms experienced by as many as
90% of cancer patients at some point during the course of
the disease [1, 2]. This high incidence of pain among cancer
suﬀerers may be due to the scarcity of elaborate studies
directed towards reducing pain speciﬁc to the cancer patient.
The study of these pain syndromes has traditionally
employedempiricaltechniquesthatinvestigate thepathome-
chanisms of pain in isolation from tumorigenesis. Pain expe-
rienced by cancer patients is often treated as a separate entity
from the cancer itself. Nevertheless, the undermanagement
ofpain canhavedrasticeﬀectsonsurvival andoverallquality
of life [3, 4]. Startling reports indicate that 46% of dying
patientslack adequatepain treatment at the time of death[3,
4]. These observations beg the need for improved methods
for cancer pain control. Furthermore, many commonly used
pharmacological approaches to cancer pain lack anatomical
speciﬁcity and often result in oﬀ-target and dose-limiting
side eﬀects that prevent lasting relief and create new sources
of suﬀering. Similarly, surgical approaches to pain lack
functional speciﬁcity, aﬀecting multiple neural systems in a
given anatomical target.
In contrast, gene therapy may provide a means to
overcome these barriers of speciﬁcity in the treatment
of cancer pain. Moreover, in the scope of chronic pain
syndromes,oncologicalpainmayprovetobeasuitableinitial
target for clinical translation. The terminal nature of many
typesof cancerlimitsthepotentialrisk ofradicalapproaches,
while the severity of the pain syndromes justiﬁes the need
for extreme innovation. Substantial advancements have been
made in viral vector design to establish gene therapy as
a viable approach for pain management. In addition, the
success of a variety of Phase I trials at demonstrating safety
in gene therapy has signiﬁcantly reduced safety concerns.
This paper will provide a rationale for the development
of new approaches to cancer pain management by making
an argument for the use of viral vector-based approaches to
modulate the nociceptive cascade. By evaluating established
approaches forpain management and preclinicalstudiesthat
determine the beneﬁts of gene therapy for chronic pain
this paper will make an argument for the translation of
these methods to the cancer patient. It is important to note
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to viral vector-derived strategies. There are a number of
gene therapy approaches that have been used to investigate
chronic pain (i.e., antisense oligonucleotides, gene silencing
methods, etc.). However, this paper is limited to the scope
of viral vector delivery of transgenes that have been shown
to result in an analgesic eﬀect. The pathways of nociception
are not summarized to reduce overlap with a number of
other reviews that eﬀectively describe molecular and cellular
mechanisms that underlie pain transmission [5–7].
The goal of this paper is to provide a comprehensive
snapshot of laboratory investigations that demonstrate the
beneﬁts of viral vector delivery of therapeutic genes as well
as highlight human studies that are aimed at determining
the safety and feasibility of gene therapy for the regulation
of pain in cancer patients. Furthermore, since the ﬁeld of
gene therapy has evolvedto includecell therapy (ex vivo gene
therapy), cellular-based approaches for pain attenuation are
alsodescribed.Itisimportanttonotethatmostofthestudies
described in this paper were not conducted in an attempt to
modulate pain speciﬁc to tumorigenesis. However, a number
of factors shown to be responsible for the generation and
maintenance of pain appear to also be involved in cancer-
related nociception, suggesting an overlap of pain signaling
pathways [8, 9]. Therefore, it is reasonable to assume that
therapies shown to be eﬀective in the absence of tumori-
genesis may oﬀer some degree of beneﬁt to cancer pain.
The substantial advancements that have been made in viral
vector technology and our increased knowledge of neuronal
circuits involved in the transmission and modulation of
somatosensory information have increased enthusiasm for
the potential success of gene and cell therapies for cancer-
related pain. Hence, gene therapy-based pain management
could prove to be a valuable interventional procedure that
sets the stage for a new class of medicines eﬀective at
alleviatingpain symptoms characteristic ofvariousetiologies
and multiple levels of severity.
2.Typesof CancerPain
Cancer pain can be either nociceptive, neuropathic, or both.
Nociceptive pain can be further distinguished as being
somatic or visceral. Somatic cancer pain usually occurs sec-
ondary to bone metastasis. It can also be due to pathological
fractures, surgery, or cancer treatment. It usually involves
the activation of inﬂammatory mediators in that tumor
and humoral factors such as prostaglandins, cytokines, and
growth factors can act locally to stimulate nociceptors. Non-
steroid anti-inﬂammatory agents (NSAIDs) are commonly
used to treat somatic pain either alone or in combination
with opiate analgesics.
Visceral cancer pain is usually poorly localized and is
sometimes referred to cutaneous points in nonvisceral areas
such as muscle or skin. This pain may not necessarily be
related to tissue injury, but can be evoked due to distension,
inﬂammation, irritation of mucosal surfaces, or impaction.
Henceatumormay goundetectedunlessitgetslarge enough
to trigger certain factors to excite normally “silent” visceral
nociceptive sensory receptors that respond to mechanical
stimuli. This information is then relayed to sympathetic and
parasympathetic eﬀerent ﬁbers that terminate in the spinal
cord. The referred pain associated with visceral nociception
is believed to be the consequence of the dual innervation or
convergence of somatic and visceral structures by common
ﬁbers. Like somatic pain, combinations of opioids and
NSAIDS are usually used to manage visceral cancer pain.
Neuropathic cancer pain results from damage to the
peripheral (PNS) and central nervous system (CNS). During
conditionsofinﬂammation orneuropathy,primary aﬀerents
can become sensitized resulting in an ampliﬁcation of
signaling and modiﬁcations in neuronal response. These
changes can cause nonnoxious stimuli to be perceived as
painful (allodynia) or result in an exaggerated response to
stimuli that is normally painful (hyperalgesia). In addition,
denervation may result in spontaneous activity in central
nociceptive neurons both at the spinal and thalamic levels.
N e u r o p a t h i cp a i ni sc o m m o ni nc a n c e ra n dc a nb e
the result of tumor nerve compression or a side eﬀect of
chemotherapy, radiation, or surgery. Cancer-related neuro-
pathic pain has been investigated using rodent or canine
models [10–18]. In most cases, bone cancer pain was
achieved by injections of tumor cells into the intramedullary
space of the tibia or femur [10, 11, 15, 16]. Nociceptive
behaviors indicative of pain such as vocalizing, guarding
of the aﬀected limb, diﬀerences in weight bearing between
hind paws, mechanical allodynia, and/or hyperalgesia as
well as neurochemical changes in the spinal cord are
commonly assessed. Additionally, animals with naturally
occurring tumors have also been utilized to evaluate cancer-
related neuropathic pain states such as the spontaneous
osteosarcoma canine modeland models ofpancreatic cancer,
benign neuroma, and squamous cell carcinoma [12–14].
Neuropathic pain in the cancer patient often results
from cancer treatment. In fact, the drugs vincristine,
paclitaxel, and cisplatin often yield neuropathic pain [15].
To understand therapy-related changes that result in cen-
tral sensitization, chemotherapy-related pain models have
been developed in rodents. These animals studies involve
either the intravenous administration of vincristine or the
intraperitoneal injection of paclitaxel or cisplatin [15]. Like
in human conditions, hypomyelination and degeneration of
dorsal roots can be observed indicating the severity of the
morphological changes induced by drug administration.
Sodium channel blockers are commonly used to treat
neuropathic cancer pain. The drawback of this therapy is
that these agents are not selective enough and can result in
undesirable eﬀects on the CNS and cardiovascular systems.
Therefore, the modulation of neurotransmitter activity by
the use of glutamate receptor antagonists (ketamine and
amantadine) or gamma-amino butyric acid (GABA) analogs
(gabapentin)canalsobeusedtoreducespontaneousﬁringin
nociceptive pathways and the dorsal horn, helping to restore
inhibitory control in the CNS [19–21].
Opiates are generally the last class of drugs to be used for
neuropathic cancer pain. Unfortunately, neuropathic pain
generallyrespondspoorlytoopiatetherapy,andconsiderable
side eﬀects are often associated with the resulting need
for high opiate doses [19, 22]. However, the coupling of
opiate-associated peptides with viral vectors for targetedPain Research and Treatment 3
opiate delivery has been eﬀective in achieving meaningful
outcomes absent in adverse reaction. Although few stud-
i e sh a v ee x p l o r e dt h ea d v a n t a g e so fg e n et h e r a p y - b a s e d
approaches to treat neuropathic cancer pain, there are, in
fact, human trials being conducted to evaluate the beneﬁts
of gene therapy for cancer pain. These investigations were
based on preclinical studies that demonstrated the analgesic
eﬀects of viral vector-driven proenkephalin expression for
the attenuation of neuropathic pain in a model of bone
cancer pain [23, 24]. These studies oﬀer a rationale for the
use of gene therapy to treat pain associated with cancer-
related conditions. By establishing models to monitor the
pathomechanisms and behavioral phenotypes associated
with the generation and maintenance of cancer pain, they
set the stage for the development of novel mechanism-based
therapeutic approaches to treat these conditions.
3.Gene Therapy
A wide range of preclinical studies have been conducted to
evaluate the eﬃcacy of gene delivery to achieve meaningful
beneﬁt in experimental models with various levels of pain
intensity. By modeling the nociceptive process that underlies
paingenerationandtransmission, thesestudieshelptodeter-
minetherelativebeneﬁtsofviralvector-basedapproachesfor
the attenuation of varying degrees of pain. Although many
of the animal pain models were not developed to evaluate
cancer-related nociception, nor do they provide a complete
recapitulation of human conditions, they are meaningful
for establishing potential therapeutics for cancer pain. As
mentioned above, pain experienced by the cancer patient
can be of a vast array. However, an understanding of these
studies helps in providing scientiﬁc rationale for applying
these approaches to cancer pain management.
The use of viral vectors for the treatment of chronic
pain involves the engineering of vector constructs in which
the potentially harmful viral genomes have been replaced
with nucleic acid sequences that encode a promoter to
drive gene expression as well as an analgesic transgene.
This approach exploits the inherent properties of the virus
which allow for cell entry and transduction. In contrast
to pharmacologic treatments, gene vectors allow for the
persistent expression of therapeutic agents following a single
administration of the viral vector rather than requiring
repeated rounds of treatment. Vector delivery also evades the
oﬀ-target side eﬀects associated with systemic opioid use as
well as avoiding the ﬁrst pass response, which diminishes the
activity of pharmacoagents before they reach the circulation.
Furthermore,viral-basedgenedeliveryrepresentsaneﬃcient
method for gene delivery to various cells and tissues.
A suitable viral vector approach for treating cancer-
related conditions would have to meet certain criteria,
however. It would have to be safe and well tolerated. It
should not elicit an immune response that would diminish
the activity of the vector or the transgene nor would it
exacerbate the pathological conditions of the cancer patient.
The virus should also be replication incompetent rendering
it incapable of producing an infection. Additionally, an
ideal vector for gene transfer would be capable of infecting
multiple cell types as well as expressing large and small
transgenes.
For the treatment of cancer pain, careful attention must
also be paid to selecting a therapeutic gene that properly
modulates the nociceptive cascade without causing addi-
tional complications to the patient. The transgene selected
should be one capable of producing a gene product that has
a known role in interfering with nociception. Such a gene
mightbeinvolvedinmodulatingneurotransmitteractivityto
regulate biochemical changes that underlie pain perception
and transmission. The potential therapeutic agent should
have known analgesic eﬀects based on its association with a
speciﬁc receptor or its ability to regulate changes in neural
tissue that mediate pain pathogenesis.
Theeﬃcacyofvector-derivedtherapeuticagentsdepends
greatly on adequate gene transfer. Adequate gene expression,
along with immune responses, remains the major limitations
for gene transfer to the CNS. Therefore, the means of vector
delivery must be carefully considered. This would involve
choosing anoptimalmethod toadminister thetherapytothe
tissues involved in facilitating the pain syndrome. Possible
approaches include targeting the neuroaxis by direct injec-
tion of sensory nerves, the spinal cord, or meninges, or the
use of vectors with inherent or engineered tropisms for the
dorsal root ganglia or other cells in the nociceptive circuitry.
3.1. Viral Vectors. A number of viral vectors are candidates
for gene delivery. Vectors derived from adenovirus (Ad),
adenoassociated virus (AAV), lentivirus, and herpes simplex
virus(HSV)havebeenusedas vehiclesfortransgene delivery
to regulate pain using a number of laboratory pain models.
These studies oﬀer particular promise for cancer pain due
to the scarcity of adequate cancer pain animal models.
Therefore, a critical examination of gene therapy approaches
used to modulate the nociceptive cascade in nonmalignant
conditions is necessary to determine the best therapeutic
strategy for cancer-associated pain conditions. Considering
the complex nature of cancer pain, in that it does not have
a singular source or origin, an understanding of successful
gene therapy eﬀorts to control pain originating from mul-
tiple sources can promote the use of the most appropriate
palliative gene therapy method for treating cancer pain.
3.1.1. Adenoviral Vectors. Adenoviral vectors are double-
stranded, nonenvelopedviralvectorsthathavebeenthemost
widely used for gene delivery [25]. Removal of the region
encoding early genes impairs viral replication, rendering
the vector suitable for gene transfer. Adenovirus can also
be puriﬁed to high titers, and early gene expression can
be achieved [25]. Furthermore, characterization of viral
tropismhasshownthatitiscapableofundergoingretrograde
axonal transport [26–30]. No oncogenic properties have
been associated with serotypes that have been used for gene
therapy (serotypes 2 and 5) [31]. Moreover, adenovirus is
a nonintegrating virus which eliminates the chance of its
interfering with the normal function of endogenous genes
[32].Nevertheless,thisalsodecreasesthestabilityofthevirus
owingtoitstransient natureandshort windowofexpression.4 Pain Research and Treatment
Consequently,adenoviralvector-mediatedgenedeliveryonly
provides transient expression. In addition, adenovirus tends
to elicit a robust inﬂammatory response, making its applica-
tion to therapy in eloquent neural structures problematic.
Adenoviral vectors have been used for the treatment of
chronic pain. Using a rodent model of chronic pain induced
by carrageenan injection into the plantar surface of the hind
paw, Finegold et al. [33] were able to achieve a reduction in
pain response at the spinal cord level. These studies helped
to establish a CNS treatment paradigm for the treatment of
chronic pain [33]. To do so, an adenoviral vector encoding
a secreted form of the neuromodulatory peptide, beta-
endorphin, was administered to the meninges surrounding
the rat spinal cord, resulting in an attenuation of thermal
hyperalgesia. Presumably beta-endorphin secretion from
meningealcellsdeliveredtheendogenousopioidtothespinal
pain circuitry via direct spread into spinal cord tissue as well
as into the cerebrospinal ﬂuid in a fashion similar to epidural
or intrathecal narcotic pumps. These studies were important
because they, for the ﬁrst time, demonstrated the ability of
a viral vector-based approach to modulate pain transmission
in vivo.
These initial studies by Finegold et al. led to additional
investigationsintotheabilityofadenoviralvectorstotransfer
therapeutic genes to target speciﬁc areas of the CNS to mod-
ulate pain [33]. Independent studies conducted by Milligan
et al. (2005) and Yao et al. (2003) using intrathecal delivery
m e t h o d si nr a t sh a v ed e m o n s t r a t e dt h ea b i l i t yo fa d e n o v i r a l
vector-driven expression of anti-inﬂammatory interleukin
(IL)-10 or IL-2, respectively, to decrease pain phenotypes
observed in sciatic nerve injury models of chronic pain [34,
35]. The antinociceptive properties of these immunoregula-
tory molecules had previously been demonstrated in studies
involving direct protein injections into rodents [34, 36–
39]. However, there was little to no justiﬁcation for their
clinical application. The short half-lives of IL-10 and IL-
2 would require frequent readministration to a sensitive
anatomical space resulting in insurmountable treatment-
related costs. To increase the expression proﬁles of IL-10,
Milligan et al. [34] generated an adenovirus expressing IL-
10 and administered it intrathecally to animals that demon-
strated thermal hyperalgesia and mechanical allodynia due
to chronic constriction injury (CCI) of the sciatic nerve.
Treated animals demonstrated decreased pain responses,
lasting for up to three weeks postvector administration,
compared to rats that had received sham surgeries [34]. In
similar studies that investigated the beneﬁts of adenovirus-
driven expression of IL-2, Yao and colleagues [35]o b s e r v e d
a decrease in sciatic nerve CCI pain response that was
maintained for up to four weeks postvector administration.
By using adenovirus to drive expression, these studies were
able to prolong the expression of these anti-inﬂammatory
cytokines, resulting in a sustained antinociceptive eﬀect [34,
35].
GABA is a major inhibitory neurotransmitter that mod-
ulates aﬀerent nociceptive transmission in the CNS and
has been shown to exhibit antinociceptive properties [40–
42]. Decreases in GABA expression induce nociceptive-
like behaviors [40, 43]. Alternatively, GABA overexpression
has been shown to attenuate the pain response. GABA is
synthesized by glutamic acid decarboxylase (GAD), and
exogenous induction of GAD can lead to increases in
GABA production that inhibit pain due to spinal cord and
peripheral nerve injury [44–46]. Interestingly, adenoviral
gene delivery of GAD to the trigeminal ganglion was able to
attenuate pain symptoms in an orofacial model of chronic
pain in which formalin was injected into the upper lip and
whisker pads of rats (P<. 001) [42].
The relevance of neurotransmitter control for pain
treatment is not limited to neuronal involvement. Astrocytes
express factors thatareimportant forneurotransmitter clear-
ance from the synaptic cleft. The glial glutamate transporter
(GLT-1) found in astrocytes has been shown to be important
for glutamate uptake which is compromised in instances of
neuropathic pain [47]. To understand the potential beneﬁts
ofincreasedglutamateremovalinconditionsofchronicpain,
an adenoviral vector was used to overexpress GLT-1 in the
spinal cord of rats. Under inﬂammatory and neuropathic
pain conditions, Ad-GLT1 was able to signiﬁcantly reduce
thermal hyperalgesia following carrageenan injection (P<
.001) and prevent tactile allodynia following spinal nerve
ligation (P<. 001) [48]. These results suggest that Ad-driven
GLT-1 overexpression in astrocytes attenuates the induction
of pain.
3.1.2.AdenoassociatedViralVectors. Adenoviralvectorscarry
certain advantages such as ease of puriﬁcation at high titers
and an ability to drive extremely robust gene expression.
However, these ﬁrst generation viral vectors had a high
incidence of immunogenicity. Thus, the inﬂammatory reac-
tion to the vector could actually act as a source of pain.
Consequently, there was a need to develop viral vectors
that could overcome these pitfalls. The use of recombinant
adenoassociated viral (AAV) vectors is currently employed.
AAV has fundamental properties that make it an attractive
gene therapy vector. AAV can also be introduced into
multiple cell types and has long-term expression [49, 50].
Additionally, it has a decreased risk of immunogenicity due
to the elimination of all viral sequences except the 145-base
pair (bp) inverted terminal repeats (ITRs) [51]. Lastly, AAV
has no etiologic association with any known diseases [51].
Many AAV serotypes have been discovered with distinct
abilities to target select tissue types. Serotype 2 has been
the most extensively studied form. As with any viral vector
approach, the vector transduction eﬃciency depends on a
number of factors. Tissue integrity, route of administra-
tion, animal age, dose and cellular immune response may
determine how eﬀectively the tissue is transduced [52, 53].
Moreover, the activity and eﬃciency of the promoters used
to drive the gene of interest may also play a unique role in
determining the expression proﬁles of the viral vectors [54].
Using AAV-driven gene expression in experimental pain
models, several studies have demonstrated that stimulation
of antinociceptive pathways in the spinal cord can decrease
pain phenotypes in rats. Brain-derived neurotrophic factor
(BDNF) has been shown to activate two major spinal cord
systems that are important for regulating the neuroaxis:
the descending modulatory serotonergic system and thePain Research and Treatment 5
inhibitoryGABAsystem.AAV-mediatedexpression ofBDNF
in the spinal cord was able to permanently reverse allodynia
and hyperalgesia caused by chronic constriction of the
sciatic nerve [55]. The changes due to the activation of
inhibitory systems were again seen using AAV vectors in
studiesinvolvingGADoverexpressionforGABAproduction.
Kim et al. have demonstrated that AAV-GAD delivered to
DRG neurons or the sciatic nerve can attenuate neuropathic
pain induced by nerve transection, with sustained eﬀects
lasting more than 3 months [41,56, 57]. These eﬀectsoﬀered
new insights into ways AAV-based approaches could be used
to treat chronic pain.
A major transducer of excitatory transmission of
the spinal cord dorsal horn is the N-methyl-D-aspartate
(NMDA) receptor. This receptor has been suggested to
be responsible for the development and maintenance of
central sensitization [58]. Therefore, antagonism of NMDA
receptors should allow for eﬀective reduction of pain
hypersensitivity following injury. Indeed, transgenic mice
engineered to express an NMDA receptor 1 (NR1) ﬂanked
by loxp sites demonstrated a 70% decrease in formalin-
induced paw pain following AAV-driven elimination of NR1
byCre-mediatedrecombination[59].Theuseofviralvectors
to deliver Cre recombinase allowed from maximum NR1
reduction in localized areas of the CNS was considered
to be critical for central sensitization initialization. NR1
elimination achievedbydirect injections ofAAV-Cre into the
lumbardorsalhornshowed thatspinallyadministered agents
remain localized, providing a rationale for the use of CNS
delivery of NR1 antagonists.
The targeting of spinal cord neurons, including both
excitatory and inhibitory postsynaptic cells, carries the
risk of unfavorable descending facilitation; however. Xu et
al. (2003) evaded this condition by targeting dorsal root
ganglia (DRG) neurons [60]. By using AAV for transgene
overexpression of the μ-opioid receptor (μ-OR) in rats,
researchers were able to achieve lasting increases in μ-OR
expression (>6 months) marked by an enhancement of the
antinociceptive eﬀects of morphine following vector-opiate
coadministration [60]. These results oﬀer an alternative
approach for the introduction of antinociceptive transgenes
for the treatment of pain. By targeting presynaptic DRG
neurons, basalnociceptiveresponses were preservedin either
normal or inﬂammatory conditions, suggesting that the use
of AAV-bearing opiate transgenes carries a substantially low
risk of tolerance development.
The idea of exploring alternative routes for vector
administration was also demonstrated by Milligan et al.
(2005) who used intrathecal delivery of AAV-IL-10 to not
only prevent, but also reverse mechanical allodynia and
thermalhyperalgesia ina ratmodelofneuropathicpain[61].
The diﬀerence in tropism of AAV serotypes is also
determined by the route of injection. In particular, AAV6 has
been shown to eﬀectively transduce nociceptive neurons of
the DRG following intrathecal delivery, a characteristic that
has not been observed using AAV2 [62–64]. However, this
increase in the vector eﬃciency of AAV6 is greatly impacted
by the route ofadministration. Althoughintrathecal delivery
of AAV6 expressing GFP results in a 60% increase in
transgene expression in DRG neurons, relatively low levels
of transduction were observed in these cells following sciatic
nerve, intramuscular, subcutaneous, and systemic injections
oftheAAV6vector[64].Thisfurther emphasizestheneedfor
careful selection of injection parameters when developing a
therapy for chronic pain.
3.1.3. Herpes Simplex Viral Vectors. The use of Herpes Sim-
plex Viral (HSV) vectors also represents a viable approach
to pain gene therapy. HSV is an enveloped, double-stranded
naturally occurring virus that has evolved a retrograde
transport mechanism and can eﬀectively transduce sensory
nerve terminals, DRG neurons, and the trigeminal ganglion
[65]. Recombinant HSV-vectors have been engineered to be
replication incompetent, yet retain the ability to undergo
retrograde transport and infect cells of the nervous system
[66–68].These vectorshavearelativelylargecloningcapacity
allowing large genes, or alternatively, multiple genes to be
inserted into the vector. HSV vectors can also be produced
to clinically relevant titers to allow for application to large-
scale human therapy.
TheinherentabilityofHSV-vectorstoinfecttheCNSand
in particular DRG neurons makes it an attractive choice for
gene-based pain control. The ﬁrst description of the eﬃcacy
and feasibility of this approach was demonstrated by Wilson
and colleagues [69] using an HSV vector to express opiate
peptides in the rat spinal cord for the attenuation of acute
pain. This resulted in an elimination of pain response lasting
for at least 7 weeks posttreatment [69].
The coupling of HSV with opioid-associated peptides
has been evaluated extensively since the early experiments
of Wilson et al. (1999) [69]. HSV-mediated delivery of
proenkephalin has been shown to have an analgesic eﬀect
in an inﬂammatory pain model of chronic pain, to be
antinociceptive following topical administration in acute
pain, to be antiallodynic in neuropathic pain, and to
attenuate nociception in a model of bone cancer pain [23,
70–72]. This approach has also been taken in the brain.
Indeed, HSV-proenkephalin injections into the amygdala
reduced pain-like behaviors and delayed the second phase of
the formalin test in rats [73].
As mentioned above, the GABAergic system is impor-
tant for pain control. Selective loss of inhibitory synaptic
current has been associated with pain development and
maintenance. To circumvent these changes an HSV-based
gene therapy approach was applied to an SNL model of
neuropathic pain. HSV-bearing glutamic acid decarboxylase
(GAD) was used to increase GABA synthesis, which reduced
pain-like behaviors in rats [44].
Certain proinﬂammatory cytokines are released in the
dorsal horn of the spinal cord in response to glia activation
duringneuropathicpain.Tumornecrosisfactor-alpha (TNF-
α) is among these molecules. To attenuate pain response
in a rat model of spinal nerve ligation, HSV was used to
drive the expression of the selective TNF-α antagonist, p55
sTNFR in DRG neurons [74]. This caused a reduction in
nociceptive behaviors characteristic of mechanical allodynia
and thermal hyperalgesia. Likewise, vector administration
of the soluble TNF-α neutralizing receptor also decreased6 Pain Research and Treatment
pain-like behaviors in a spinal cord injury pain model [75].
These results collectively highlight the beneﬁts of suppressed
TNF-α activity in the treatment of pain and the importance
of modifying the inﬂammatory cascade in chronic pain
conditions. Indirect approaches that increase the expression
of anti-inﬂammatory cytokines are known to interfere with
TNF-αexpression. For example, increased expression of IL-4
with an HSV vector approach has been shown to produce
antiallodynic eﬀects. This is due to the ability of IL-4 to
regulate TNF-α activity [76].
DRG-regulated control of nociceptive transmission has
also been investigated using HSV-driven expression of
neurotrophic factors known to reverse sensory abnormal-
ities associated with neuropathic pain. Glial-derived neu-
rotrophic factor (GDNF) is a member of the transforming
growth factor-β superfamily that is abundantly expressed in
the central and peripheral nervoussystems. Increased GDNF
expression has demonstrated a neuroprotective quality in a
variety of models of neurodegenerative disease. These obser-
vations suggest that it has therapeutic value for a number
of disorders such as Parkinson’s disease, Amyotrophic lateral
sclerosis, and stroke [77–79]. In relation to pain, intrathecal
HSV-mediated GDNF overexpression has been shown to
be antinociceptive and to reduce allodynia following sub-
cutaneous administration in a rodent model of SNL pain.
Nevertheless, these eﬀects were short lived resulting in a
subsequent decline 2.5 weeks after injection [80].
3.1.4. Lentiviral Vectors. Lentiviral vectors are some of the
most promising vectors for clinical application. Lentiviral
vectors can achieve stable transgene expression, elicit a
minimal inﬂammatory response, and infect both dividing
and nondividing cells, including neurons [81, 82]. They can
also achieve retrograde transport and are the most widely
used vectors for gene transfer to the CNS. Most lentiviral
vectors are based on human immunodeﬁciency virus type
1 (HIV-1). However, other types including the nonpri-
mate equine infectious anemia virus (EIAV) and the feline
immunodeﬁciency virus (FIV) have been employed [83–85].
Studies utilizing the HIV-1 and the EIAV virus for trans-
gene expression of GDNF have shown that vector pretreat-
mentintothespinalcordofadultratresultsinareducedpain
response following SNL [86]. Robust transgene expression
was observed in both neurons and glial cells. Lentiviral vec-
tors also achieved partial reversal of thermal and mechanical
allodynia, demonstrating that this vector approach was able
to eﬀectively modify conditions of neuropathic pain [86].
The functional relevance of modulating pain-inducing
factors in glial cells was also evaluated using a sciatic nerve
injury model of pain in rats. Not only is pain associated
with altered neuronal function, but aberrant conditions in
spinalglialcellscanaidinactivatingthenociceptivesignaling
pathway. Nuclear factor-κβ (NF-κβ) has been shown to
exacerbate pain by facilitating proinﬂammatory conditions
in activated spinal glial cells [46, 87]. Lentivirus-directed
expression of a selective NF-κβ suppressor into the spinal
cord was shown to markedly reduce pain response following
chronic nerve constriction injury as well as result in a
downregulation of proinﬂammatory cytokines [88].
3.2. Gene Therapy Considerations. Despite remarkable
advances in viral vector technology and the vast array of
preclinical studies conducted to evaluate vector eﬃcacy
in a number of diseases, there are considerable challenges
that still remain. One issue relates to viral vector targeting.
In order for any viral vector to have therapeutic value
it is necessary that measures be taken to ensure eﬃcient
transgene delivery to the appropriate cells with limited
nontargeted eﬀects. A lack of appropriate targeting could
substantially hinder therapy eﬃcacy. However, certain
approaches have been taken to improve vector tropism.
The use of cell type-speciﬁc promoters can increase
appropriate localization of transgene as well as decrease the
possibility of oﬀ-target cell infection. Moreover, approaches
that involve the modiﬁcation of cell attachment proteins
have also been developed for lentiviral and AAV vectors
[89, 90]. Speciﬁcally in AAV vector production, AAV2 vector
genomes responsible for replication can be packaged with
variant AAV capsids to create pseudotyped vectors. Due to
the natural tropism of diﬀerent AAV serotypes for certain
tissues, these hybrid systems can allow for optimal targeting
of a speciﬁc cell or tissue type. Moreover, the ﬁeld has also
evolved to the degree in which modiﬁcations can be made
in capsid proteins to create chimeric vectors with increased
insertion capacity and tropism [90]. Also, certain viruses
have a natural propensity for tissue speciﬁcity as is the case
with HSV vectors that inherently infect the CNS. Therefore,
careful selection of the best promoter and vector system
could allow for increased cell targeting.
Increased cell targeting does not always lead to improved
viral transduction eﬃciency, however. It has been shown
that ubiquitination and degradation of capsids substantially
limits their ability to reach the nucleus. To overcome this,
AAV capsid domains subject to ubiquitination have been
mutated to allow for increased vector stability, achieving up
to a 100-fold increase in transgene expression [89, 91].
Cell-speciﬁc targeting and improved transduction are
only a few concerns associated with viral vector use.
Vector production costs often limit the translation of viral
vector approaches to the clinical setting. Moreover, several
rounds of clinical trials are often required to establish the
optimal clinical protocol for maximum therapeutic beneﬁt.
Consideration of the route of administration (i.e., systemic
versus localized treatment), dose, and the potential for
toxic eﬀects must also be evaluated when establishing a
treatment protocol involving gene therapy approaches. If
the advances are realized, viral vector-mediated transgene
delivery could provide promise for a number of chronic
conditions including cancer pain.
4.Cell Therapy
Cell transplantation therapy also appears to be a possi-
ble approach for the treatment of pain. Chromaﬃn cells
naturally release substances shown to be eﬀective in mod-
ulating pain transmission [92, 93]. These factors include
GABA, galanin, serotonin, and met-enkephalin. Injection
of chromaﬃn cells into the lumbar subarachnoid space
reduces nociceptive behaviors in the formalin test (P<. 05)Pain Research and Treatment 7
[94]. Moreover, cell transplantation for pain has also been
achieved using various cell lines that overexpress substances
with known antinociceptive properties. Neuronal cells from
a number of sources including human (hNT2.17 cell line)
have been modiﬁed to secrete GABA, serotonin, galanin,
or BDNF [95–100]. Transplantation of these cells results in
reversal/reduction of pain-like behaviors in rodent models
of chronic pain. Moreover, spinal cord injection of neural
precursor cells induced to diﬀerentiate into a GABAergic
phenotype is also suggested to be an eﬀective strategy for
reducing pain [101].
Glial cells (microglia, astrocytes, and oligodendrocytes)
are found in the CNS and respond to changes that occur
in the neuronal environment. They have been shown to
engage in bidirectional communication with neurons to
facilitate changes in the nervous system. One way these
cells regulate conditions in the CNS is by expressing and
interacting with chemical molecules that modulate the pain
response to nerve injury. In particular, astrocytes have been
shown to be activated in neuropathic pain conditions [102,
103]. To understand if astrocytes could be bioengineered to
display a positive role in pain regulation, an inducible gene
system was used to overexpress proenkephalin in astrocytes.
Transfected cells wereimplanted intothesubarachnoid space
of rats. Mechanical and thermal hyperalgesia produced by
chronic constriction of the sciatic nerve was evaluated.These
studies found that the regulated release of the opioid peptide
was able to attenuate neuropathic pain in rats [104]. The
application of glial cell transplantation for the delivery of
therapeutic molecules to the CNS was further emphasized
using galanin secreting cells [105]. In these studies, immor-
talized galanin-overexpressing astrocytes were injected into
the subarachnoid space of rats with chronic pain from sciatic
nerve injury. Cell transplantation was able to eﬀectively
attenuate thermal hyperalgesia and mechanical allodynia for
up to seven weeks after cell transplantation [105].
The beneﬁts of stem cells and cells with stem cell-like
properties have also been evaluated for the treatment of
chronic pain. Embryonic stem cells transplanted into the
spinal cord of rats that had spinal cord injuries not only
reducedtissue damage, butalso attenuated the pain response
in both the formalin and von Frey hair tests [106]. Human
mesenchymal stem cells (hMCs) have also been used to
r e d u c ep a i ns y m p t o m si nr o d e n tp a i nm o d e l s .M i c et h a t
received hMCs treatment to the lateral cerebral ventricle
following sciatic nerve injury displayed reduced pain-like
behaviors compared to controls [107].
5.ClinicalTrials
Currently there is an on-going trial for cancer pain. Wolfe
et al. began the ﬁrst human gene therapy trial for cancer
pain in 2008 [24, 108]. A phase 1 study based on preclinical
studies that deﬁned the beneﬁts of a replication-defective
HSV vector-bearing preproenkephalin will determine the
safety of intradermal vector injections into patients with
intractable cancer pain [23, 24, 108]. It is a dose escalating
trial initiative that involves patients with moderate to severe
malignant disease. Primary outcome measures of this study
are adverse events and dose. Eﬃcacy of the therapy will be
assessed as a secondary measure determined by a numeric
pain rating scale and the concurrent use ofpainmedications.
A subsequent phase 2 trial will evaluate the beneﬁts of
HSV-preproenkephalin in patients with inﬂammatory pain.
Individuals with chronic intractable focal pain from arthritis
represent an ideal population to target [24]. Data obtained
fromthese eﬀortshopetosetthestageforclinicalevaluations
of the beneﬁts of HSV-mediated GAD expression for the
treatment of chronic pain. Preclinical studies have provided
substantial evidence for the eﬀectiveness of GAD overpro-
duction in the attenuation of pain. Consequently, a clinical
grade HSV-expressing GAD vector has been constructed and
iscurrentlybeingevaluatedinarodentmodelofneuropathic
pain due to spinal nerve ligation [24]. If successful, Wolfe
et al. hope to use this as support for an expedited clinical
research initiative to evaluate HSV-GAD in a phase 2 trial
in patients suﬀering from painful diabetic neuropathy [24].
Taken together, these research investigations could establish
HSV gene therapy as a viable approach for the clinical
treatment of chronic pain.
6.EmergingStrategies
Aberrant neural activity is a characteristic feature of con-
ditions of chronic pain. A substantial population of cancer
patients experience intractable cancer pain with varying
etiologies. Careful consideration must be taken when devel-
oping therapies for this patient population. Cell transplan-
tation therapies always carry concerns of tumorigenesis,
graft rejection, cell migration, proliferation, and viability.
Therapies developed using opiate peptides are only partially
eﬀective and may be subject to the same mechanisms of
tolerance seen with pharmacological therapy. Regulation
of neurotrophic factor expression, although shown to be
beneﬁcial in attenuating pain in laboratory models, cannot
be assigned a strict antinociceptive function. Furthermore,
it would be challenging to determine an eﬀective dose for
treatment. Activating or downregulating members of the
immune system could have unexpected adverse events in
that these cytokines and chemokines often play a role in
multiple regulatory systems. Therefore, a targeted approach
for local pain inhibition could have particular relevance for
the treatment of cancer pain.
Clostridial neurotoxins are assuming substantial clinical
relevance. The family of clostridial neurotoxins includes
botulinum toxins (BoNT) and tetanus toxin (TeTx). Each
protein consists of both a heavy and a light chain separated
by a disulﬁde bond. These subunits dissociate following
cell entry. The light chain contains the catalytic activity,
whereas the heavy chain is responsible for cell internal-
ization. Depending on the subtype, the light chain of
clostridial neurotoxins cleaves one of the three SNARE
proteins necessary for neurotransmitter release. Without
the heavy chain, the light chain cannot achieve neuronal
binding, yet its proteolytic activity remains intact. Therefore
focal delivery of the light chain to target a select neuronal
population is a viable approach for treating a number of
conditions involving aberrant neuronal discharge.8 Pain Research and Treatment
Several possible uses for clostridial toxins have been
proposed. In relation to cancer pain, focal injections of
BoNT have been used to reduce the intensity and frequency
of pain due to leiomyomas (skin tumors) and have been
proposed for the treatment of bone cancer pain [8, 109].
Support for BoNT translation to the cancer patient lies
in its demonstrated ability to suppress key mediators of
pain transmission and factors that have been hypothesized
to regulate cancer nociception [8, 110, 111]. Such factors
include substance P, endothelin-1, and calcitonin gene-
related peptide (CGRP) [8, 9, 112]. Unfortunately, there are
no known studies investigating the usefulness of BoNT gene
transfer for the treatment of any condition.
The beneﬁts of gene transfer of TeTx light chain
(TeTx.LC) in isolation of tumorigenesis and pain have
been evaluated in our laboratory. Considering the common
mode of action between BoNT and TeTx, these studies
provide a basis for the exploration of gene-based neural
inhibition using viral vectors expressing TeTx.LC. Using an
adenovirus-based vector approach, we have demonstrated
the ability of TeTx.LC to inhibit neural activity following
direct injections into the spinal cord of rodents [113]. In
these studies, adult rats received ipsilateral injections of
Ad.TeTx.LC into the lumbar spinal cord. Hindlimb paralysis
was used as an outcome measure of neuronal inhibition.
At the peak of transgene expression we reported no loss
of motor neurons, cell death, or adverse events related
to vector administration. Moreover, due to the transient
nature of adenoviral vectors, we were able to determine
that motor functional changes induced by spinal cord
injection of Ad.TeTx.LC were reversible, indicating a lack
of reorganization of neural networks and neurotoxic eﬀects.
These studies oﬀer compelling evidence that this vector-
based approach could be used to modulate conditions of
chronic pain involving excessive neuronal ﬁring. Moreover,
since thisis a pathophysiologicalfeature ofcancerpain, these
studies invite the investigation of viral vector delivery of
TeTx.LC using protocols established for safe focal delivery of
therapies to the CNS.
7.Conclusions
Gene therapy is an exciting prospect for the treatment
and management of cancer-related pain. Advances in viral
vector design and increased understanding of the signaling
systems that underlie pain generation, transmission, and
maintenance havehelped to establish gene-based approaches
as a potentially eﬀective means to modulate nociception
in a number of diseases. The application of these gene
therapy tools using cancer pain laboratory models provides
substantial insight into the molecular and biological fea-
tures of virus-derived vectors under tumorigenic conditions.
Animal work with state-of-the-art gene therapy technology
demonstrates the feasibility of targeted gene expression of
factors that play a known role in the nociceptive cascade.
Considering the high prevalence of pain among the cancer
patient population, the development of viral vector-based
therapy techniques is timely and necessary. Moreover, since
the etiology of the pain experienced by cancer patients can
arise from a sensory neuropathy distinct from the cancer
itself (i.e., therapy side eﬀect or diagnostic and surgical
procedures), a mechanistic approach to cancer-associated
pain is crucial to improving the quality and survival of
the cancer patient. Therefore, careful selection of transgene
and vector system must be taken into consideration when
designing studies aimed at addressing conditions of cancer
pain. Clinical investigations to assess the safety, tolerability,
and beneﬁts of gene-based therapies promise to direct the
ﬁeld towards focal continuous delivery of analgesic peptides
to selectively disrupt nociceptive signaling with limited
oﬀ-target eﬀects. Although some risk still remains, gene
therapy-basedpainmanagementcouldprovetobeavaluable
interventional procedure that sets the stage for a new class of
medicines which are eﬀective at alleviating pain symptoms
that are associated with a number of disorders.
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